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TCT-164
Is Amplatzer Duct Occluder II Ideal for Closure of Congenital Gerbode’s Defect?
Huliyur Durga Srinivasa Setty N Setty1, Vijayalakshmi IB2,
Ravindranath K Shankarappa1, Chitra N Narasimhan3, Manjunath C. Nanjappa1
1Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore,
Karnataka, 2Sri jayadeva Institute of Cardiovascular Sciences & Research,
Bangalore, Karnataka, India, 3Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bangalore, KARNATAKA
Background: Gerbode defects are rare (0.08%), congenital left ventricular to right
atrial communications. The congenital syndrome of left ventricular-right atrial
communication was ﬁrst described by Thurman in 1838. The advent of echocardi-
ography, particularly color Doppler imaging, has improved the noninvasive diagnosis
of intracardiac shunts. They are traditionally closed surgically with high incidence of
complete heart block. But there are no reports of congenital left ventricular-right atrial
shunts closed by devices. For the ﬁrst time we are report a small series of six cases of
Gerbode’s defect closed by Amplatzer Duct Occluder II. Aim of our study is to assess
the feasibility, efﬁcacy of trans catheter closure of Gerbode’s defect by Amplatzer
Duct Occluder II.
Methods: Six consecutive cases of Gerdode defect, age ranging from 10 months to
13 years formed the material. The weight ranged from 6.5 kgs to 34 kgs. The size of
the defect ranged from 4 to 6 mm on transthoracic echocardiography (TTE).
Results: The left ventricular angiogram done in AP, RAO view with 10 0 cranial
angulation illustrated the contrast from LV opacifying the right atrium (RA). The
defect was crossed by over the wire technique by 0.0 25” Terumo guide wire through
the retrograde approach from aorta. 4F Cooks Shuttle sheath was passed over the
guide wire. The distal retention skirt was released in RA and the whole system was
pulled under ﬂuoroscopy and TTE guidance. The devices were deployed in all the
patients by releasing the middle lobe at the defect and the proximal disc in LV. The
defects were successfully closed with various sizes of ADO II 4X6 in 2 cases,3X4,
5X4,6X6 in one case each. Only one patient had transient complete heart block
needing temporary pacing for 48 hours and steroids for ﬁve days. He made a complete
recovery. The ﬂuoroscopic time was 6.2 +1.4 min. No tricuspid regurgitation or re-
sidual shunt in any of the patients on
Conclusions: ADO II is safe, effective and an attractive alternative to surgical closure
of Gerbode defects.ADO II is ideal for closure as the success rate is very high with
very low complication rate and on short-term follow-up results are favourable.
TCT-165
Transcatheter pulmonary valve replacement with the Edwards-Sapien Valve:
The Toronto Congenital Cardiac Centre for Adults Experience
William Wilson1
1University of Toronto, Toronto, Canada
Background: Percutaneous pulmonary valve implantation (PPVI) has emerged as a
viable alternative to surgery in patients with right ventricular outﬂow tract (RVOT)
dysfunction. Limited data is available for the Sapien (Edwards Lifesciences, Irvine
CA) valve in this setting.
Methods: Retrospective analysis of all patients to have undergone PPVI using the
Sapien valve at a large quaternary centre. Continuous variables presented as mean-
standard deviation, categorical as percentages. Comparisons between means are
made using the t-test.
Results: 23 patients (74% male, mean age 349.2 years) were identiﬁed. Mean pre-
procedure NYHA class was 2.50.7 and maximum VO2 was 186ml/kg/min (53 
11% predicted). Primary diagnosis was: Tetralogy of Fallot (n¼13), Ross procedure
(n¼5), PA/IVS (n¼2), DORV/Rastelli (n¼1), ccTGA (n¼1), PS (n¼1). RVOT char-
acteristics included: homograft (n¼9), bioprosthesis (n¼7), valved conduit (n¼5), failed
Melody valve within a homograft (n¼2). Nature of conduit dysfunction was: stenosis
(n¼8), regurgitation (n¼6) or combined stenosis/regurgitation (n¼9). Technical success
was 96%. One patient required elective surgical pulmonary valve replacement for a high
residual gradient. Pre-stenting was performed in all. Valve sizes were 23mm (n¼8),
26mm (n¼14) and 29mm (n¼1). Procedural haemodynamics revealed a decrease in the
mean RV-to-systemic pressure ratio from 0.64 to 0.36 (p< 0.001) and RV-to-PA
gradient from 39 to 9mmHg (p< 0.001). At a mean follow-up of 3.62.1 years (range
0.5-7.2 years), there were no deaths and no endocarditis episodes. One patient required
re-intervention (no PR immediately post procedure but severe valvar PR at one year
requiring a valve in valve procedure). 74% were NYHA class 1 (mean1.20.5) and the
mean VO2 max was 196ml/kg/min (6013 % predicted, p¼0.09 compared to pre-JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Coprocedure). There was preserved valve function during serial follow up (no change in the
RVSP (mean 509mmHg, p¼0.78) nor PV peak gradient (mean 2510mmHg,
p¼0.22) compared to initial post procedure echocardiogram). Pulmonary regurgitation
was trace in 82% and mild in 14% by echocardiography.
Conclusions: The Edwards Sapien valve is a viable and durable option for PPVI in
this single centre study.
TCT-166
Stenting the Right Ventricular Outﬂow Tract as a Palliative Procedure in
Patients with Tetralogy of Fallot
Carlos Pedra1, Rodrigo Costa2, Marcelo Ribeiro3, Wanda Nascimento4,
Simone Pedra4, Glaucio Furlanetto4, Marcelo Jatene3, Patricia Elias3,
Virginia Santana4, Valmir Fontes4
1Instituto Dante Pazzanese de Cardiologia., São Paulo, Brazil, 2Dante Pazzanese,
Sao Paulo, Brazil, 3Hospital do Coração, Sao Paulo, Brazil, 4Dante Pazzanese,
Sao Paulo, Brazil
Background: Neonates and infants with Tetralogy of Fallot (TOF) may occasionally
need a BTT shunt to treat hypoxemia. However it may distort the anatomy of the pul-
monary arteries (PAs). We report the outcomes after stenting the right ventricular
outﬂow tract (RVOT) as an alternative procedure to temporarily improve pulmonary
blood ﬂow.
Methods: From January 2010, stenting the RVOT was offered as an alternative pro-
cedure to BTT shunt. The procedure was performed under general endotracheal anes-
thesia. One or more coronary or peripheral stents (4-8 mm in diameter) were implanted
in the RVOT across the pulmonary valve annulus using 4-6 F catheters. Pre-dilation was
performed according to the operator preference. Nor or epinephrine infusion was used
during the procedure as appropriate. Technical success, procedural complications,
hypoxemia control and feasibility of surgical repair were all outcomes parameters.
Results: Nine patients (median age and weight: 3 months and 5 kgs (1.5-10),
respectively) underwent the procedure. One patient had complete AVSD, one had
previous BTT shunt and another had Alagille syndrome. Three underwent concomi-
tant procedures (PA angioplasty and balloon aortic valvuloplasty). All stents were
implanted in the intended location with signiﬁcant improvement in the systemic
arterial saturations from 708 to 825% (p< 0.05) and no procedural complications.
In one 3 month-old premie (1.5 kgs), the procedure allowed for PGs discontinuation.
Moderate to severe PI was observed in all patients. One with Alagille syndrome, aortic
stenosis and hypertrophic cardiomyopathy had intractable CHF and died of sepsis 2
weeks afterwards. Another infant died at another center 6 months afterwards due to
intractable hypoxemia. In the remaining 7 patients, peak systolic gradient by echo was
a median of 55 mmHg (30-70) before surgical repair, which was performed un-
eventfully 2-90 days after the percutaneous procedure. The previously implanted
stents were easily removed at the operation.
Conclusions: In this initial experience, stenting the RVOT was feasible, safe and
effective in the short-term. Continuous and close monitoring should be performed and
deﬁnitive surgical repair should not be delayed.
TCT-167
Coarctation Stenting Through the Carotid Approach in Neonates and Infants
Carlos Pedra1, Luis O. Campaña2, Marcelo Ribeiro3, Rodrigo Costa4,
Paulo Chaccur2, Fabiana Succi5, Glaucio Furlanetto2, Virginia Santana2,
Simone Pedra2, Valmir Fontes2
1Instituto Dante Pazzanese de Cardiologia., São Paulo, Brazil, 2Dante Pazzanese,
Sao Paulo, Brazil, 3Hospital do Coração, Sao Paulo, Brazil, 4Dante Pazzanese,
Sao Paulo, Brazil, 5Hospital do Coração, Sao Paulo, Brazil
Background: Coarctation of the aorta (CoA) may present with congestive heart
failure (CHF) in the neonate and infant. Balloon angioplasty is generally ineffective
due to high rates of restenosis. We report mid-term outcomes after CoA stenting
through the carotid artery (CA) in this age group.
Methods: CoA stenting was performed under endotracheal general anesthesia. The
common CA was dissected out by the CV surgeon and a 4-7F sheath placed under
direct vision. Stents that could be dilated up to the adult aorta size were mounted on
5-9 mm balloons. Stents were not crossed after delivery. The CA was repaired at the
end of the procedure with 8.0 prolene individual sutures. Doppler ultra-sound was
used to assess CA patency during follow-up.
Results: From0/07,20 pts (median age andweight: 4.5months and5.3kgs, respectively)
underwent the procedure. Ten had native and 10 recurrent CoA. Eleven had isolatedCoA
and 9 had CoA associated with complex CHD such as TGA, interrupted aortic arch and
univentricular hearts. LV dysfunction was present in 11 pts requiring intravenous ino-
tropes in 6. In all pts stentswere implanted in the intended locationwith diameter increase
from 2.4 0.8 to 6.5 1.2 mm (p< 0.001). There were no complications. The CA was
repaired uneventfully. CHF was controlled in 19/20 patients, which resulted in discon-
tinuation of inotropes. The echo gradient fell from 38 12 to 8 7 mmHg (p< 0.001).
CADoppler performed in 10 patients showed normal ﬁndings. In amedian follow up of 2
years, all patients were clinically well, with normal blood pressure and distal pulses.
Three pts underwent reinterventions (2 patients: new stents, one for aneurysm formation
and the other for neointimal proliferation; and 1 redilation to adjust for somatic growth), 1
underwent a hybrid reintervention (stent dilation + intracardiac repair) and 2 underwent
surgical repair of complex CHD. There were 2 deaths after surgery.ngenital Heart Disease, Complex B49
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: CoA stenting through theCA in neonates and infantswas feasible safe and
effective in the short-to-mid-term. New procedures should be performed during follow
up to adjust for somatic growth, treat complications or repair intracardiac lesions.
TCT-168
Short Term follow up of Percutaneuos Closure Of Perimembranous Ventricular
Septal Defects Using The Second Generation Amplatzer Occluders
Makram R. Ebeid1, Sarosh Batlivala2, Ahmad Charaf Eddine2, Avichal Aggarwal2,
Jorge Salazar2, Mary Taylor2
1University of Mississippi Medical center, Jackson, MS, 2University of Mississippi
Medical Center, Jackson, MS
Background: No devices are currently available in the USA for percutaneous closure
of perimembranous (Pm) ventricular septal defects (VSDs). The earlier device was
withdrawn from clinical trial because of development of heart block possibly related to
over sizing and/or device rigidity. New, softer devices are available for vascular oc-
clusions as the Amplazer Vascular Plug II (AVP II) and the Amplatzer Duct Occluder
II (ADO II). We previously submitted our initial experience in occluding Pm VSDs
using AVP II & ADO II in 10 patients (pts) using AVP II in 6 and ADO II in 4. This is
follow up (f/up) of these pts and additional pt.
Methods: F/up data of these pts. were reviewed speciﬁcally assessing for the devel-
opment of heart block, residual ﬂow through the device, presence of aortic insufﬁciency
(AI) and device embolization or fracture or the occurrence of late adverse events (AE).
Results: Review of F/up data of these pts. was performed speciﬁcally assessing for the
development of heart block, residual ﬂow through the device, presence of aortic
insufﬁciency (AI) and device embolization or fracture or the occurrence of late
adverse events (AE).
Results: F/up clinical evaluations, chest x-rays and echocardiograms were available
for all patients expect 1 who did not undergo chest x ray because of pregnancy. F/up
period ranged from 0-13 months with a median of 5.5 + 5. New AI was seen in 3
patients graded as mild in 1 and trivial in 2. In 1 patient the AI could have been
preexisting and masked by the VSD ﬂow. 1 patient had mild new Tricuspid regur-
gitation. There was no incidence of device fracture or late embolization and no clinical
evidence of hemolysis, sub-acute bacterial endocarditis or any serious AE. No patient
developed heart block. In 1 patient with elongated tunnel type VSD, the device took
the conﬁguration of the defect. 1 patient had residual ﬂow through the device which
disappeared on follow up. I patient has additional small VSD.
Conclusions: In our series, percutaneous closure of PmVSDs using the softer new
generation devices as the AVP II and the ADO II appears to be safe in the short term.
Flow seen through the device usually disappears as the device endothelializes.
TCT-169
Exit Angiography and Intraoperative Stenting after Surgical Repair of Complex
Congenital Heart Disease in a Hybrid Room: Impact on Management Strategies
and Outcomes
Carlos Pedra1, Rodrigo Costa2, Marcelo Ribeiro3, Paulo Chaccur4,
Glaucio Furlanetto4, Magaly Arrais5, Ana L. Guerra4, Virginia Santana4,
Simone Pedra4, Valmir Fontes4
1Instituto Dante Pazzanese de Cardiologia., São Paulo, Brazil, 2Dante Pazzanese,
sSao Paulo, Brazil, 3Hospital do Coração, Sao Paulo, Brazil, 4Dante Pazzanese, Sao
Paulo, Brazil, 5Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: Residual lesions after surgical repair of complex congenital heart dis-
ease (CHD) are poorly tolerated. An exit angiography (EA) after cardiopulmonary
bypass (CPB) has been performed to promptly diagnose residual lesions, which may
result in a change of the management strategy. We report our initial experience with
EA and intraoperative stenting (IOS) in a dedicated hybrid suite (HS).
Methods: Patients (pts) with complex CHD were selected for EA at multidisci-
plinary meetings. All procedures were conducted in a dedicated HS in the OR.
Catheters were advanced through sheaths secured by purse string sutures in the
RVOT, SVC, MPA or ascending aorta. Stent delivery was guided by ﬂuoroscopy
after CPB completion.
Results: From 05/12 to 05/14, EA was performed in 22 pts (median age and weight:
0.9 years and 9.2 kg, respectively) after surgical repair (Glenn operations, uni-
focalization, bioprosthetic valve insertion, complex CoA). Twelve patients (55%)
required IOS with 14 stents implanted in the PAs or descending aorta (1). The decision
to implant a stent was made before hand in 4 pts and only after EA was performed in 8
pts (2 pts had undergone a failed redo surgical PA plasty under CPB after an initial
EA). In all patients, stents were placed in the intended location and resulted in sig-
niﬁcant increase of vessel diameter from a median of 3.7 to 8.5 mm (p< 0.001). There
were no deaths or vascular complications during the procedure. Of those 12 patients
who underwent IOS, 8 pts had an uneventful early postoperative period. Two pts died
in the ICU (1 pt with complex univentricular heart and 1 pt with HLHS in ECMO after
Norwood-Glenn operation) and 1 patient each needed hemodialysis and peri-
cardiocentesis, respectively, not related to EA or IOS. Of those 10 pts in whom IOS
was not performed, surgical results were considered adequate and post-op course was
uneventful.
Conclusions: EA and IOS were feasible, safe and effective. EA should be carefully
planned before surgery in selected patients and may result in changes in management
strategies. IOS probably results in better immediate surgical outcomes.B50 JACC Vol 64/11/Suppl B j SepLeft Atrial Appendage Exclusion
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Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device
Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial
Fibrillation
Vivian W. Lee1, Bryan Yan1, Ines Chow1, Ping Ching Tsai1, Yat-Yin Lam1
1The Chinese University of Hong Kong, Hong Kong, China
Background: Transcatheter left atrial appendage occlusion (LAAO) is a promising
therapy for stroke prophylaxis in non-valvular atrial ﬁbrillation (NVAF) but its cost-
effectiveness remains understudied.
Methods: A Markov decision analytic model was used to compare cost-effectiveness
of LAAO with 7 alternative strategies: Aspirin alone, Clopidogrel plus Aspirin,
Warfarin, Dabigatran (110 and 150mg), Apixaban, and Rivaroxaban. This model
simulates a cohort of 65-year-old NVAF patients moving between different health
statuses in each Markov cycle of 1 year. The time horizon was lifetime (85 years old).
Health states include AF without event, with event before, ischemic cerebrovascular
events, hemorrhage, myocardial infarction, vascular or non-vascular deaths. To esti-
mate discounted (3%) lifetime costs, quality-adjusted life years (QALYs) and incre-
mental cost-effectiveness ratios (ICERs). Base-case data were derived from ACTIVE,
RE-LY, PROTECT-AF and PREVAIL trials. One-way sensitivity analysis varied by
HAS-BLED scores and time horizons, and probabilistic sensitivity analysis (PSA)
using Monte Carlo simulations were conducted to assess parameter uncertainty.
Results: Compared with Aspirin alone, Clopidogrel plus Aspirin, Warfarin, Dabigatran
110mg, LAAO was cost-effective with an ICER of $3,921, $2,226, $3431, and $58 per
QALY gained, respectively; however, LAAO was dominant to Dabigatran 150mg,
Apixaban, and Rivaroxaban strategies (i.e. less costly and more effective). Sensitivity
analysis demonstrated signiﬁcant performance in ICERs of LAAO against oral antico-
agulant drugs for patients with increasing HAS-BLED scores and within the varied time
horizons (5, 10, and 15 years), and LAAO strategy was cost-effective over 99% of the
Monte Carlo simulation using a cost-effectiveness threshold of US$50,000/QALY.
Conclusions: Transcatheter LAAO strategy is considered cost-effective as compared
with 7 other antithrombotic strategies for prevention of stroke in patients with NVAF
regardless of their risks of ischemic stroke.
TCT-171
Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage
Closure compared with Long-Term Oral Anticoagulation: A Pooled Analysis of
Randomized Trials
Matthew J. Price1, Miguel Valderrabano2, Kenneth Huber3, Scott S. Wehrenberg4,
Nicole Gordon4, Kenneth M. Stein4, David Holmes5
1Scripps Clinic, La Jolla, United States, 2Methodist Hospital, Houston, TX, 3St. Luke’s
Mid America Heart Institute, Kansas City, MO, 4Boston Scientiﬁc, St Paul, MN,
5Mayo Clinic College of Medicine, Rochester, United States
Background:WATCHMAN left atrial appendage (LAA) closure is a novel approach
to preventing stroke in patients with atrial ﬁbrillation (AF) that could reduce the
longer-term risk of bleeding compared with anticoagulation. We compared the tem-
poral incidence of major bleeding beyond the immediate procedural period in the
randomized trials of the device.
Methods: Landmark analyses of time-to-ﬁrst major bleed in the PROTECT-AF,
PREVAIL, and pooled trials were performed for 3 periods: (1) from 8-to-45 days post-
procedure, during which WATCHMAN patients received warfarin; (2) from 46-to-
180 days, during which WATCHMAN patients received dual antiplatelet therapy
(DAPT); and (3) beyond 180 days, when WATCHMAN patients were eligible to
receive aspirin alone. Major bleeding was site-reported and adjudicated as a serious
adverse event by the Clinical Events Committee.
Results: After the periprocedural period, the risk of major bleeding did not differ
signiﬁcantly between study arms when WATCHMAN patients received warfarin or
DAPT. Beyond 6 months, the bleeding risk was signiﬁcantly lower with the device
strategy compared with long-term warfarin (Hazard Ratio [HR] 0.30 [95% Conﬁdence
Interval (CI): 0.17-0.53), a ﬁnding that was consistent across trials (PROTECT-AF:
HR 0.31 [95% CI: 0.16-0.61]; PREVAIL, HR 0.27 [95% CI: 0.09-0.79]).tember 13–17, 2014 j TCT Abstracts/Left Atrial Appendage Exclusion
